Inducible_JJ
nuclear_JJ
factor_NN
binding_NN
to_TO
the_DT
kappa_NN
B_NN
elements_NNS
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
enhancer_NN
in_IN
T_NN
cells_NNS
can_MD
be_VB
blocked_VBN
by_IN
cyclosporin_NN
A_NN
in_IN
a_DT
signal-dependent_JJ
manner_NN
._.

Cyclosporin_NN
A_NN
-LRB-_-LRB-
CsA_NN
-RRB-_-RRB-
is_VBZ
thought_VBN
to_TO
exert_VB
its_PRP$
immunosuppressive_JJ
effects_NNS
by_IN
inhibiting_VBG
the_DT
expression_NN
of_IN
a_DT
distinct_JJ
set_NN
of_IN
lymphokine_NN
genes_NNS
which_WDT
are_VBP
induced_VBN
upon_IN
T-cell_NN
activation_NN
,_,
among_IN
them_PRP
the_DT
gene_NN
coding_VBG
for_IN
interleukin-2_NN
._.

In_IN
addition_NN
,_,
the_DT
activation_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
-LRB-_-LRB-
HIV_NN
-RRB-_-RRB-
is_VBZ
partially_RB
suppressed_VBN
._.

To_TO
better_RBR
understand_VB
the_DT
molecular_JJ
mechanisms_NNS
underlying_VBG
suppression_NN
by_IN
CsA_NN
,_,
we_PRP
have_VBP
investigated_VBN
the_DT
effects_NNS
of_IN
this_DT
drug_NN
on_IN
transcription_NN
factors_NNS
in_IN
T_NN
cells_NNS
._.

Here_RB
we_PRP
report_VBP
that_IN
the_DT
formation_NN
of_IN
two_CD
distinct_JJ
mitogen-inducible_JJ
DNA-binding_JJ
complexes_NNS
,_,
the_DT
kappa_NN
B_NN
complex_NN
within_IN
the_DT
HIV_NN
enhancer_NN
and_CC
the_DT
NFAT-1_NN
complex_NN
within_IN
the_DT
interleukin-2_NN
enhancer_NN
,_,
is_VBZ
inhibited_VBN
in_IN
the_DT
presence_NN
of_IN
CsA_NN
._.

The_DT
kappa_NN
B-binding_JJ
activity_NN
with_IN
the_DT
HIV_NN
enhancer_NN
is_VBZ
inhibited_VBN
only_RB
if_IN
it_PRP
is_VBZ
activated_VBN
via_IN
the_DT
mitogen_NN
phytohemagglutinin_NN
whereas_IN
phorbol_NN
myristate_NN
acetate-mediated_JJ
activation_NN
is_VBZ
completely_RB
insensitive_JJ
to_TO
the_DT
drug_NN
._.

This_DT
suggests_VBZ
a_DT
model_NN
in_IN
which_WDT
functionally_RB
indistinguishable_JJ
kappa_NN
B_NN
complexes_NNS
can_MD
be_VB
activated_VBN
via_IN
two_CD
separate_JJ
pathways_NNS
of_IN
signal_NN
transduction_NN
distinguishable_JJ
by_IN
CsA_NN
._.

